Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice
M Yan, W Li, WB Li, Q Huang, J Li, HL Cai… - Drug Metabolism …, 2023 - Taylor & Francis
At present, receptor tyrosine kinase signaling-related pathways have been successfully
mediated to inhibit tumor proliferation and promote anti-angiogenesis effects for cancer …
mediated to inhibit tumor proliferation and promote anti-angiogenesis effects for cancer …
Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
J Liu, S Yan, J Du, L Teng, R Yang, P Xu, W Tao - Heliyon, 2024 - cell.com
Tyrosine kinase inhibitors (TKIs) have become first-line drugs for cancer treatment. However,
their clinical use is seriously hindered since many patients experience diarrhea after …
their clinical use is seriously hindered since many patients experience diarrhea after …
[HTML][HTML] Identification of potential therapeutic dual inhibitors of EGFR/HER2 in breast cancer
M Jethwa, A Gangopadhyay, A Saha - European Journal of Medicinal …, 2024 - Elsevier
Breast cancer (BC) is the leading cause of death among women worldwide. According to the
Breast Cancer Research Foundation (BCRF), 25% of all cases of BC are positive for human …
Breast Cancer Research Foundation (BCRF), 25% of all cases of BC are positive for human …
[HTML][HTML] Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
L Zhang, A Hu, Y Wang, Y Yang, Y Liu, L Xu, L Wang… - Neoplasia, 2023 - Elsevier
Afatinib, as the first-line treatment for non-small cell lung cancer (NSCLC), causes severe
gastrointestinal adverse reactions that greatly affect patients' quality of life and even …
gastrointestinal adverse reactions that greatly affect patients' quality of life and even …
Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer
J Blanter, E Baldwin, R Patel, T Sheng… - Breast Cancer Research …, 2024 - Springer
Purpose One year of neratinib therapy is known to derive a significant invasive disease-free
survival (iDFS) benefit in early-stage, hormone receptor-positive (HR+), HER2+, node …
survival (iDFS) benefit in early-stage, hormone receptor-positive (HR+), HER2+, node …
Effects of Tokishakuyakusan, Keishibukuryogan, and Kamishoyosan on the expression and activity of drug-metabolizing enzymes in the liver and small intestine
K Yokoyama, K Tabata, Y Shinozaki, R Saito… - Pharmacological …, 2024 - Elsevier
The mechanisms of action of traditional herbal medicines are being actively researched, but
little information is available regarding the interactions of these agents with concomitant …
little information is available regarding the interactions of these agents with concomitant …
Neratinib, a clinical drug against breast cancer, protects against atherosclerosis via ASK1 inhibition
F Zhang, Y Yin, Z Wang, X Wu, D Kamato, J Weng… - bioRxiv, 2024 - biorxiv.org
Atherosclerosis commences with endothelial dysfunction and the retention of cholesterol
within the vessel wall, followed by a chronic inflammatory response. Cholesterol-lowering …
within the vessel wall, followed by a chronic inflammatory response. Cholesterol-lowering …
[HTML][HTML] Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II
M Enghelberg, S Kaifee - Cureus, 2023 - ncbi.nlm.nih.gov
The purpose of this case report is to present the first case of neratinib maculopathy. We
describe the initial presentation, baseline characteristics, imaging findings, and outcomes …
describe the initial presentation, baseline characteristics, imaging findings, and outcomes …
Development of Nanoparticle Delivery System for Taxane and Small Molecule Tyrosine Kinase Inhibitors for the Treatment of HER2-Positive Breast Cancer
B Mandala - 2024 - search.proquest.com
This study aims to develop and assess the effectiveness of docetaxel and small tyrosine
kinase inhibitors (STKIs: Tucatinib/Neratinib/Lapatinib) loaded stealth polymeric …
kinase inhibitors (STKIs: Tucatinib/Neratinib/Lapatinib) loaded stealth polymeric …
Patterns in Use and Tolerance of Adjuvant Neratinib in Patients With Hormone Receptor-Positive, HER2-Positive Early-Stage Breast Cancer
J Blanter - 2024 - search.proquest.com
One year of adjuvant neratinib therapy derives a significant invasive disease-free survival
benefit in patients with Hormone receptor-positive (HR+), HER2+, node-positive breast …
benefit in patients with Hormone receptor-positive (HR+), HER2+, node-positive breast …